# Ruizheng Gene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruizheng-gene

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.accuredit.com
- Latest round: Seed (Sep 9, 2021)
- Investors on record: 2

## About

Established in 2021 and based in Suzhou, China, Ruizheng Gene was founded to develop gene and RNA editing technologies for therapeutic applications. The founder, chairman, and CEO Dr. Yongzhong Wang has over 20 years of experience in biopharmaceutical innovation, having held leadership roles at CMAB BioPharma (Suzhou), Simcere Pharmaceutical Group, and Chengdu Kanghong Biotechnology. Co-founder and head of CMC, Dr. Jialin Tao, previously worked at Roche, CMC Biologics, Simcere, and CMAB. In August 2025, Ruizheng Gene raised CNY 75 million in series A funding from new investors Xizang Nuodikang Pharmaceutical and China Medical System Holdings Limited. The company develops innovative drug candidates and treatment solutions targeting intracellular and nuclear disease mechanisms. Its core technologies include gene editing, RNA editing and delivery platforms integrated with off-target analysis and process development for congenital and acquired disease therapies. The company generates revenue through partnerships, licensing, and early-stage therapeutic product development focused on genetic and RNA-based treatments. The company plan to use the series A funding to accelerate optimization of its core technology platforms, advance its therapeutic pipelines, and expand R&D capabilities for genetic and acquired disease treatments.

## Funding rounds

- Seed, Sep 9, 2021 — Legend Capital, Cormorant Asset Management

## Investors

- Legend Capital — Seed
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Seed